WESPAC Advisors LLC Sells 652 Shares of AstraZeneca PLC (NASDAQ:AZN)

WESPAC Advisors LLC decreased its stake in AstraZeneca PLC (NASDAQ:AZN) by 6.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,190 shares of the company’s stock after selling 652 shares during the period. WESPAC Advisors LLC’s holdings in AstraZeneca were worth $794,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. McClarren Financial Advisors Inc. raised its position in AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after acquiring an additional 247 shares in the last quarter. GHP Investment Advisors Inc. acquired a new stake in AstraZeneca in the 2nd quarter valued at about $26,000. Capital Performance Advisors LLP bought a new position in AstraZeneca during the third quarter worth about $28,000. Pathway Financial Advisers LLC acquired a new position in AstraZeneca during the first quarter worth approximately $29,000. Finally, CANADA LIFE ASSURANCE Co raised its stake in AstraZeneca by 40.6% in the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after buying an additional 146 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Performance

Shares of NASDAQ:AZN opened at $65.63 on Friday. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The company’s 50 day moving average price is $73.44 and its two-hundred day moving average price is $77.80. The firm has a market cap of $203.49 billion, a PE ratio of 31.40, a PEG ratio of 1.20 and a beta of 0.47. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The business had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.87 earnings per share. Equities research analysts predict that AstraZeneca PLC will post 4.1 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. TD Cowen upped their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Finally, UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.